Clinical Trial Update: The PROLONG Trial - Rituximab Maintenance Therapy in ITP [Phase 3]

View source ↗

Summary

A Phase 3 trial update for the PROLONG study evaluating rituximab as maintenance therapy in immune thrombocytopenia; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Ostfold Hospital Trust | Conditions: Purpura, Thrombocytopenic, Idiopathic | Phase 3 | Status: UNKNOWN